Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
Status: Enrolling
Updated:  10/5/2015
Overlook Hospital
mi
from
Summit, NJ
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
Status: Enrolling
Updated: 10/5/2015
Overlook Hospital
mi
from
Summit, NJ
Click here to add this to my saved trials
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
Status: Enrolling
Updated:  10/5/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
Status: Enrolling
Updated: 10/5/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/5/2015
Memorial Sloan-Kettering Cancer Center
mi
from
NY, NY
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/5/2015
Memorial Sloan-Kettering Cancer Center
mi
from
NY, NY
Click here to add this to my saved trials
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Rio Negro,
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Rio Negro,
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Cleveland Clinic Florida
mi
from
Weston, FL
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Jacobi Medical Center
mi
from
Bronx, NY
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Jacobi Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Cleveland Clinic
mi
from
Cleveland, OH
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Abramson Cancer Center
mi
from
Philadelphia, PA
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
UT Southwestern
mi
from
Dallas, TX
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
UT Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
The Mayo Clinic
mi
from
Rochester, MN
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  10/5/2015
Peninsula Oncology Centre
mi
from
Frankston,
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 10/5/2015
Peninsula Oncology Centre
mi
from
Frankston,
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Moores Cancer Center University of California, San Diego, Site #099
mi
from
La Jolla, CA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Moores Cancer Center University of California, San Diego, Site #099
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
UC Irvine Medical Center/Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
UC Irvine Medical Center/Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Kaiser Permanente
mi
from
San Diego, CA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Kaiser Permanente
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Yale Cancer Center
mi
from
New Haven, CT
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Cancer Center of South Florida
mi
from
Lake Worth, FL
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Cancer Center of South Florida
mi
from
Lake Worth, FL
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
University of Chicago
mi
from
Chicago, IL
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
UNC Health Care; N.C. Cancer Hospital Infusion/Inpatient Pharmacy (CHIP)
mi
from
Chapel Hill, NC
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
UNC Health Care; N.C. Cancer Hospital Infusion/Inpatient Pharmacy (CHIP)
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Levine Cancer Institute-Concord/Clinical Trials (Site 056)
mi
from
Charlotte, NC
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Levine Cancer Institute-Concord/Clinical Trials (Site 056)
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Hospital of the University of Pennsylvania, Perelman Center for Advanced Medicine (Site 013)
mi
from
Philadelphia, PA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Hospital of the University of Pennsylvania, Perelman Center for Advanced Medicine (Site 013)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
Swedish Cancer Institute
mi
from
Seattle, WA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
City of Hope
mi
from
Duarte, CA
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
University of Colorado Cancer Center
mi
from
Aurora, CO
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
The Mayo Clinic
mi
from
Rochester, MN
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated:  10/5/2015
St Vincent's Hospital Melbourne (Site997)
mi
from
Fitzroy,
A Phase 2, Multicenter, Randomized Study of AP26113
A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Status: Enrolling
Updated: 10/5/2015
St Vincent's Hospital Melbourne (Site997)
mi
from
Fitzroy,
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated:  10/5/2015
UCLA, Center for Clinical AIDS Research and Education
mi
from
Los Angeles, CA
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated: 10/5/2015
UCLA, Center for Clinical AIDS Research and Education
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated:  10/5/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated: 10/5/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated:  10/5/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated: 10/5/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated:  10/5/2015
Montefiore Medical Center-Einstein Campus
mi
from
Bronx, NY
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated: 10/5/2015
Montefiore Medical Center-Einstein Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated:  10/5/2015
University of California, San Diego
mi
from
San Diego, CA
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status: Enrolling
Updated: 10/5/2015
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
An Observational Cohort Study on Transplant-Related Mortality in Patients Receiving Either a Hematopoietic Stem Cell Transplantation Without ATIR or an Umbilical Cord Blood Transplantation
Status: Enrolling
Updated:  10/5/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
An Observational Cohort Study on Transplant-Related Mortality in Patients Receiving Either a Hematopoietic Stem Cell Transplantation Without ATIR or an Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 10/5/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
An Observational Cohort Study on Transplant-Related Mortality in Patients Receiving Either a Hematopoietic Stem Cell Transplantation Without ATIR or an Umbilical Cord Blood Transplantation
Status: Enrolling
Updated:  10/5/2015
Algemeen Ziekenhuis Sint-Jan
mi
from
Brugge,
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
An Observational Cohort Study on Transplant-Related Mortality in Patients Receiving Either a Hematopoietic Stem Cell Transplantation Without ATIR or an Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 10/5/2015
Algemeen Ziekenhuis Sint-Jan
mi
from
Brugge,
Click here to add this to my saved trials
Psychotherapy for Depressed or Anxious Adolescents With Cancer
Open Trial of Behavioral Activation Therapy for Depressed or Anxious Adolescents With Cancer
Status: Enrolling
Updated:  10/5/2015
New York State Psychiatric Institute
mi
from
New York, NY
Psychotherapy for Depressed or Anxious Adolescents With Cancer
Open Trial of Behavioral Activation Therapy for Depressed or Anxious Adolescents With Cancer
Status: Enrolling
Updated: 10/5/2015
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Comprehensive Cancer Institute
mi
from
Huntsville, AL
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Comprehensive Cancer Institute
mi
from
Huntsville, AL
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated:  10/5/2015
MBCCOP - Gulf Coast
mi
from
Mobile, AL
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
MBCCOP - Gulf Coast
mi
from
Mobile, AL
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated:  10/5/2015
Providence Alaska Medical Center
mi
from
Anchorage, AK
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Providence Alaska Medical Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated:  10/5/2015
CCOP - Western Regional, Arizona
mi
from
Phoenix, AZ
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
CCOP - Western Regional, Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated:  10/5/2015
CCOP - Mayo Clinic Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
CCOP - Mayo Clinic Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials